Hong Kong · Delayed Price · Currency is HKD Nanjing Leads Biolabs Statistics
Total Valuation
HKG:9887 has a market cap or net worth of HKD 12.33 billion. The enterprise value is 11.33 billion.
| Market Cap | 12.33B |
| Enterprise Value | 11.33B |
Important Dates
The last earnings date was Monday, August 31, 2026.
| Earnings Date | Aug 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:9887 has 195.12 million shares outstanding. The number of shares has increased by 25.82% in one year.
| Current Share Class | 193.90M |
| Shares Outstanding | 195.12M |
| Shares Change (YoY) | +25.82% |
| Shares Change (QoQ) | +2.73% |
| Owned by Insiders (%) | 7.34% |
| Owned by Institutions (%) | 15.45% |
| Float | 144.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 50.10 |
| PB Ratio | 11.48 |
| P/TBV Ratio | 11.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 46.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.41, with a Debt / Equity ratio of 0.40.
| Current Ratio | 2.41 |
| Quick Ratio | 2.08 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28.34 |
Financial Efficiency
Return on equity (ROE) is -51.55% and return on invested capital (ROIC) is -16.34%.
| Return on Equity (ROE) | -51.55% |
| Return on Assets (ROA) | -12.87% |
| Return on Invested Capital (ROIC) | -16.34% |
| Return on Capital Employed (ROCE) | -23.73% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 950,429 |
| Profits Per Employee | -1.19M |
| Employee Count | 259 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, HKG:9887 has paid 21.48 million in taxes.
| Income Tax | 21.48M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.59% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -3.59% |
| 50-Day Moving Average | 63.09 |
| 200-Day Moving Average | 62.62 |
| Relative Strength Index (RSI) | 44.12 |
| Average Volume (20 Days) | 2,016,130 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:9887 had revenue of HKD 246.16 million and -308.20 million in losses. Loss per share was -1.59.
| Revenue | 246.16M |
| Gross Profit | 246.16M |
| Operating Income | -257.81M |
| Pretax Income | -286.71M |
| Net Income | -308.20M |
| EBITDA | -240.63M |
| EBIT | -257.81M |
| Loss Per Share | -1.59 |
Balance Sheet
The company has 1.43 billion in cash and 431.07 million in debt, with a net cash position of 1.00 billion or 5.14 per share.
| Cash & Cash Equivalents | 1.43B |
| Total Debt | 431.07M |
| Net Cash | 1.00B |
| Net Cash Per Share | 5.14 |
| Equity (Book Value) | 1.07B |
| Book Value Per Share | 5.51 |
| Working Capital | 970.49M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 17.39M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -104.73% and -125.20%.
| Gross Margin | 100.00% |
| Operating Margin | -104.73% |
| Pretax Margin | -116.47% |
| Profit Margin | -125.20% |
| EBITDA Margin | -97.75% |
| EBIT Margin | -104.73% |
| FCF Margin | n/a |
Dividends & Yields
HKG:9887 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.82% |
| Shareholder Yield | -25.82% |
| Earnings Yield | -2.50% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for HKG:9887 is 103.15, which is 68.27% higher than the current price. The consensus rating is "Buy".
| Price Target | 103.15 |
| Price Target Difference | 68.27% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 59.55% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |